摘要
心房纤颤（简称“房颤”）是临床最常见的心律失常，发病率和死亡率均较高。目前在美国大约有2300000房颤患者，英国每年大约新诊断房颤46000例以上。房颤的患病率在50～59岁年龄组为0．5％，而在70岁以上年龄组则增至9％。房颤常和其他一些心血管疾病并存，如高血压、心力衰竭、动脉粥样硬化，而这些并存的疾病均是发生房颤的独立危险因素。最近的研究表明肾素-血管紧张素-醛固酮系统（RAAS）抑制对房颤患者是有益的。
Atrial fibrillation （AF）, the commonest cardiac arrhythmia in clinical practice, is associated with substantial morbidity and mortality. Atrial fibrillation currently affects about 2.3 million individuals in the United States. In the United King- dom alone, more than 46 000 new cases of atrial fibrillation are diagnosed every year. The prevalence of atrial fibrilla- tion increases from O. 5% in the age group 50- 59y to 9% in those older than 70y. AF commonly coexists with other common cardiovascular disorders such as hypertension, heart failure, and atherosclerotic vascular disease, which are all important independent risk factors of developing AF. Recent researches have suggested the benefits of the
